PL3248597T3 - Środek terapeutyczny na niedosłuch czuciowo-nerwowy - Google Patents

Środek terapeutyczny na niedosłuch czuciowo-nerwowy

Info

Publication number
PL3248597T3
PL3248597T3 PL16740038.1T PL16740038T PL3248597T3 PL 3248597 T3 PL3248597 T3 PL 3248597T3 PL 16740038 T PL16740038 T PL 16740038T PL 3248597 T3 PL3248597 T3 PL 3248597T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
hearing loss
sensorineural hearing
sensorineural
loss
Prior art date
Application number
PL16740038.1T
Other languages
English (en)
Inventor
Makoto Hosoya
Masato Fujioka
Hideyuki Okano
Kaoru Ogawa
Tatsuo Matsunaga
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of PL3248597T3 publication Critical patent/PL3248597T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16740038.1T 2015-01-19 2016-01-13 Środek terapeutyczny na niedosłuch czuciowo-nerwowy PL3248597T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015007849 2015-01-19
PCT/JP2016/050861 WO2016117431A1 (ja) 2015-01-19 2016-01-13 内耳性難聴治療薬

Publications (1)

Publication Number Publication Date
PL3248597T3 true PL3248597T3 (pl) 2024-06-24

Family

ID=56416978

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16740038.1T PL3248597T3 (pl) 2015-01-19 2016-01-13 Środek terapeutyczny na niedosłuch czuciowo-nerwowy

Country Status (10)

Country Link
US (2) US11058669B2 (pl)
EP (2) EP3295939B1 (pl)
JP (2) JP6716139B2 (pl)
DK (1) DK3248597T3 (pl)
ES (2) ES2978203T3 (pl)
FI (1) FI3248597T3 (pl)
HU (1) HUE067321T2 (pl)
PL (1) PL3248597T3 (pl)
PT (1) PT3248597T (pl)
WO (1) WO2016117431A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101785455B1 (ko) * 2016-03-16 2017-11-20 전남대학교산학협력단 귀리 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 약제학적 조성물
US12097218B2 (en) * 2017-05-26 2024-09-24 Kite Pharma, Inc. Methods of making and using embryonic mesenchymal progenitor cells
JP6999896B2 (ja) 2017-09-21 2022-01-19 学校法人慶應義塾 音響外傷難聴モデル動物の作製方法及びそれにより作製される音響外傷難聴モデル動物
CN108310386A (zh) * 2018-04-09 2018-07-24 南方医科大学 mTOR信号通路抑制剂在制备预防或治疗非遗传性听力障碍药物中的用途
JP2023106640A (ja) * 2020-06-09 2023-08-02 株式会社オトリンク 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物
CN117157071A (zh) * 2021-04-23 2023-12-01 延世大学校产学协力团 包含自噬激活剂作为活性成分的组合物用于预防或治疗非综合征性常染色体显性耳聋
KR20250122535A (ko) * 2022-12-30 2025-08-13 주식회사 아보메드 약학적 활성 화합물, 조성물 및 펜드린 조절 방법
WO2025239443A1 (ja) * 2024-05-16 2025-11-20 学校法人北里研究所 加齢性難聴の治療又は予防薬のスクリーニング方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3963495B2 (ja) 1995-05-22 2007-08-22 生化学工業株式会社 アポトーシス惹起抑制剤
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
WO2001051049A1 (en) * 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
JP2004123713A (ja) 2002-08-05 2004-04-22 Mitsubishi Pharma Corp 突発性難聴の予防及び/又は治療のための医薬
JP2004099537A (ja) * 2002-09-10 2004-04-02 Sanwa Kagaku Kenkyusho Co Ltd 難聴疾患の予防又は治療剤
WO2005009287A2 (en) * 2003-07-21 2005-02-03 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
JP2008539276A (ja) 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
TWI457336B (zh) 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
CN101687798B (zh) * 2007-05-17 2012-08-15 金克斯医药品有限公司 制备用于调节激酶级联的组合物的过程及其使用方法
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
WO2010118419A2 (en) 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them

Also Published As

Publication number Publication date
EP3248597A4 (en) 2018-10-10
JP2017200923A (ja) 2017-11-09
JP6716139B2 (ja) 2020-07-01
JP6708346B2 (ja) 2020-06-10
FI3248597T3 (fi) 2024-04-17
WO2016117431A1 (ja) 2016-07-28
EP3248597B1 (en) 2024-03-13
US11013725B2 (en) 2021-05-25
HUE067321T2 (hu) 2024-10-28
ES2928593T3 (es) 2022-11-21
DK3248597T3 (da) 2024-04-08
US20170340586A1 (en) 2017-11-30
US11058669B2 (en) 2021-07-13
EP3295939A1 (en) 2018-03-21
ES2978203T3 (es) 2024-09-06
US20170333403A1 (en) 2017-11-23
PT3248597T (pt) 2024-03-25
EP3248597A1 (en) 2017-11-29
JPWO2016117431A1 (ja) 2017-11-02
EP3295939B1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
SG10201912416QA (en) Therapeutic agents
AU367792S (en) Loudspeaker
EP3199628A4 (en) Cytotoxicity-inducing therapeutic agent
GB201509893D0 (en) Therapeutic agents
GB201509283D0 (en) Hearing aid
PL3373882T3 (pl) Izolator pacjenta
GB201517263D0 (en) Therapeutic agents
PT3248597T (pt) Agente terapêutico para a perda auditiva neurossensorial
DK3470112T3 (en) Cochlear implantat
SI3254474T1 (sl) Elektroakustični implantat
GB201509885D0 (en) Therapeutic agents
GB201518214D0 (en) Loudspeaker
SG11201709260TA (en) Therapeutic agent for fibrosis
GB2546067B (en) Loudspeaker
GB2537353B (en) Earphone
GB201516297D0 (en) Loudspeaker
GB201509888D0 (en) Therapeutic agents
GB201513299D0 (en) Therapeutic agents
GB201717279D0 (en) Identifier
EP3305311A4 (en) Brain function-protecting agent
PL3306953T3 (pl) Głośnik
GB201521767D0 (en) Therapeutic agents
AU201611783S (en) Loudspeaker
GB201517264D0 (en) Therapeutic agents
GB201501003D0 (en) In-ear monitor